Search

Orion Oyj (Class B)

Slēgts

61.35 -2.31

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

61.35

Max

62.55

Galvenie mērījumi

By Trading Economics

Ienākumi

119M

180M

Pārdošana

62M

417M

P/E

Sektora vidējais

25.353

37.003

EPS

0.59

Dividenžu ienesīgums

2.4

Peļņas marža

43.289

Darbinieki

3,700

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.40%

2.25%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

718M

9.6B

Iepriekšējā atvēršanas cena

63.66

Iepriekšējā slēgšanas cena

61.35

Orion Oyj (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 30. okt. 23:32 UTC

Karstas akcijas

Stocks to Watch: Amazon, Reddit, SPS Commerce

2025. g. 30. okt. 23:02 UTC

Peļņas

AIA Group 3Q Value of New Business Grew

2025. g. 30. okt. 23:45 UTC

Tirgus saruna

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

2025. g. 30. okt. 23:00 UTC

Peļņas

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

2025. g. 30. okt. 22:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 30. okt. 22:59 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

2025. g. 30. okt. 22:56 UTC

Tirgus saruna

Australia Shares Shaping to Pare Recent Losses -- Market Talk

2025. g. 30. okt. 22:35 UTC

Peļņas

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

2025. g. 30. okt. 22:35 UTC

Peļņas

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

2025. g. 30. okt. 22:31 UTC

Peļņas

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

2025. g. 30. okt. 22:29 UTC

Peļņas

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

2025. g. 30. okt. 22:27 UTC

Peļņas

Minas Buenaventura 3Q EPS 66c >BVN

2025. g. 30. okt. 22:27 UTC

Peļņas

Minas Buenaventura 3Q Rev $431M >BVN

2025. g. 30. okt. 22:27 UTC

Peļņas

Minas Buenaventura 3Q Net $179M >BVN

2025. g. 30. okt. 22:16 UTC

Tirgus saruna
Peļņas

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

2025. g. 30. okt. 22:14 UTC

Peļņas

Review & Preview: A Tech Earnings Storm -- Barrons.com

2025. g. 30. okt. 22:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

2025. g. 30. okt. 21:39 UTC

Peļņas

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025. g. 30. okt. 21:26 UTC

Peļņas

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025. g. 30. okt. 21:14 UTC

Tirgus saruna
Peļņas

Apple Sees Record Quarterly Services Revenue -- Market Talk

2025. g. 30. okt. 21:09 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 30. okt. 21:09 UTC

Tirgus saruna
Peļņas

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

2025. g. 30. okt. 21:04 UTC

Peļņas

Apple Expects Big December Quarter on iPhone Upgrades -- Update

2025. g. 30. okt. 21:03 UTC

Peļņas

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

2025. g. 30. okt. 21:03 UTC

Peļņas

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

2025. g. 30. okt. 21:00 UTC

Peļņas

Eldorado Gold Skouries on Track for 1Q of 2026

2025. g. 30. okt. 21:00 UTC

Peļņas

Eldorado Gold 3Q Adj EPS 41c >EGO

2025. g. 30. okt. 21:00 UTC

Peļņas

Eldorado Gold 3Q Rev $434.7M >EGO

2025. g. 30. okt. 21:00 UTC

Peļņas

Eldorado Gold 3Q Net $56M >EGO

2025. g. 30. okt. 21:00 UTC

Peļņas

Eldorado Gold 3Q EPS 27c >EGO

Orion Oyj (Class B) Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
help-icon Live chat